The Brain Eye Amyloid Memory (BEAM) Study: Validation of Ocular Measures as Potential Biomarkers for Early Detection of Brain Amyloid and Neurodegeneration
The BEAM study, sponsored by Sunnybrook Health Sciences Centre, aims to validate non-invasive ocular measurements as biomarkers for early detection of neurodegenerative diseases, including Alzheimer's Disease and Mild Cognitive Impairment. This study is positioned in a growing market focused on early diagnostics for dementia, which is increasingly critical as the global aging population expands. The findings could enhance the competitive landscape for diagnostic tools in neurodegeneration, potentially leading to partnerships or licensing opportunities with companies specializing in ocular imaging and neurodegenerative diagnostics. The study's collaboration with GE Healthcare indicates a strategic alignment with industry leaders, enhancing its commercial viability.
Indication: Alzheimer's Disease
Modality: radioligand therapy
Target: Ocular measures as potential biomarkers for early detection of brain amyloid and neurodegeneration.
Sponsor: Sunnybrook Health Sciences Centre
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Ocular measures as potential biomarkers for early detection of brain amyloid and neurodegeneration.
View original source fields
Condition raw: Alzheimer's Disease, Mild Cognitive Impairment, Vascular Cognitive Impairment, Parkinson's Disease, Lewy Body Disease
Condition normalized: Alzheimer's Disease, Mild Cognitive Impairment, Vascular Cognitive Impairment, Parkinson's Disease, Lewy Body Disease
Modality raw: radioligand therapy
Modality normalized: radioligand therapy
Target raw: Ocular measures as potential biomarkers for early detection of brain amyloid and neurodegeneration.
Target normalized: Ocular measures as potential biomarkers for early detection of brain amyloid and neurodegeneration.